Constitutive IL-10 Production Accounts for the High NK Sensitivity, Low MHC Class I Expression, and Poor Transporter Associated with Antigen Processing (TAP)-1/2 Function in the Prototype NK Target YAC-1
The DOI matches its Crossref record.
Abstract
Tumor cells that are treated with rIL-10 or transfected with the IL-10 gene show phenotypic changes. These include low but peptide-inducible expression of MHC class I, low sensitivity to specific CTL-mediated lysis, and increased NK sensitivity. In vitro-established mouse tumor lines were screened for IL-10 expression and production, and a large proportion of plasmocytomas or T cell lymphomas were found to produce IL-10. Since one of these lines was the prototype NK target cell YAC-1, we investigated whether the high IL-10 production of this cell line was related to its high NK sensitivity and its defects in MHC class I expression. The decrease in H-2 expression following the in vitro culture of in vivo-passaged YAC-1 cells was accompanied by a gradual increase in IL-10 production, whereas the reverse was found when passing in vitro-grown YAC-1 in vivo as an ascites tumor in syngenic mice. In addition, differences in YAC-1 MHC class I expression correlated with alterations in the functional activity of TAP-1/2 proteins. YAC-1 cells that were transduced with a retroviral IL-10 antisense construct (Y-IL-10 AS) only produced about half of the IL-10 that was produced by YAC-1 transduced with the control construct (Y-IL-10 Mock). Relative to Y-IL-10 Mock cells, the expression of H-2 on Y-IL-10 AS cells was markedly increased, and NK sensitivity was decreased. These data argue for a mechanism wherein IL-10 production is causally related to the low H-2 expression, decreased TAP function, and high NK sensitivity of YAC-1 cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Interleukin-10 and the Interleukin-10 Receptor
Moore, K. W., de Waal Malefyt, R., Coffman, R. L., & O'Garra, A. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.683 · Cited by 6,737
Prognostic value of intratumoral natural killer cells in gastric carcinoma
Ishigami, S., Natsugoe, S., Tokuda, K., Nakajo, A., Che, X., Iwashige, H., Aridome, K., Hokita, S., & Aikou, T. (2000) · Cancer · doi:10.1002/(sici)1097-0142(20000201)88:3<577::aid-cncr13>3.0.co;2-v · Cited by 586
The paradoxical role of IL-10 in immunity and cancer
Mannino, M. H., Zhu, Z., Xiao, H., Bai, Q., Wakefield, M. R., & Fang, Y. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.07.009 · Cited by 473
Mocellin, S. (2003) · Trends in Immunology · doi:10.1016/s1471-4906(02)00009-1 · Cited by 463
Antigen-processing machinery breakdown and tumor growth
Seliger, B., Maeurer, M. J., & Ferrone, S. (2000) · Immunology Today · doi:10.1016/s0167-5699(00)01692-3 · Cited by 459
Interleukin-10 and the immune response against cancer: a counterpoint
Mocellin, S., Marincola, F. M., & Young, H. A. (2005) · Journal of Leukocyte Biology · doi:10.1189/jlb.0705358 · Cited by 402
Vaccines for tumour prevention
Lollini, P.-L., Cavallo, F., Nanni, P., & Forni, G. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1815 · Cited by 340
Current status of interleukin-10 and regulatory T-cells in cancer
Dennis, K. L., Blatner, N. R., Gounari, F., & Khazaie, K. (2013) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000006 · Cited by 289
“IL-10 could also compromise immune surveillance by changing immunogenicity of the antigen-presenting cell through down-regulation of transporter associated with antigen processing, and therefore antigen presentation by MHC-I and human leukocyte antigen-I [94,95].”
BackgroundCytokines and Immune Response in the Tumor Microenvironment
Mocellin, S., Wang, E., & Marincola, F. M. (2001) · Journal of Immunotherapy · doi:10.1097/00002371-200109000-00002 · Cited by 259
Mocellin, S., Marincola, F., Riccardo Rossi, C., Nitti, D., & Lise, M. (2004) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2003.11.001 · Cited by 247
“In vitro, IL-10 downregulates the transport of peptides and MHC class I expression [(TAP)-1/2] in YAC-1 cells [164], which precludes TAA epitope recognition by CD8+ T cells.”
BackgroundResultParadoxical effects of cytokines in tumor immune surveillance and tumor immune escape
Salazar-Onfray, F., López, M. N., & Mendoza-Naranjo, A. (2007) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2007.01.015 · Cited by 194
Self-citationThe human papillomavirus (HPV)-related cancer biology: An overview
Araldi, R. P., Sant’Ana, T. A., Módolo, D. G., de Melo, T. C., Spadacci-Morena, D. D., de Cassia Stocco, R., Cerutti, J. M., & de Souza, E. B. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.06.149 · Cited by 192
Histone deacetylases and the immunological network: implications in cancer and inflammation
Villagra, A., Sotomayor, E. M., & Seto, E. (2010) · Oncogene · doi:10.1038/onc.2009.334 · Cited by 192
Strategies for immunotherapy of cancer
Melief, C. J. M., Toes, R. M., Medema, J. P., Van Der Burg, S. H., Ossendorp, F., & Offringa, R. (2000) · Advances in Immunology · doi:10.1016/s0065-2776(00)75006-1 · Cited by 165
MHC Class I Antigens and Immune Surveillance in Transformed Cells
Aptsiauri, N., Cabrera, T., Garcia‐Lora, A., Lopez‐Nevot, M. A., Ruiz‐Cabello, F., & Garrido, F. (2007) · International Review of Cytology · doi:10.1016/s0074-7696(07)56005-5 · Cited by 145
Metadata
- Authors
- Petersson, M., Charo, J., Salazar-Onfray, F., Noffz, G., Mohaupt, M., Qin, Z., Klein, G., Blankenstein, T., & Kiessling, R.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 1998-09-01
- Volume
- 161
- Issue
- 5
- Pages
- 2099-2105
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1604235714
- Cited by
- 109
- References
- 0
- FWCI
- 3.58
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.